Thrombin Activatable Fibrinolysis Inhibitor (TAFI): An Updated Narrative Review

Int J Mol Sci. 2021 Apr 1;22(7):3670. doi: 10.3390/ijms22073670.

Abstract

Thrombin activatable fibrinolysis inhibitor (TAFI), a proenzyme, is converted to a potent attenuator of the fibrinolytic system upon activation by thrombin, plasmin, or the thrombin/thrombomodulin complex. Since TAFI forms a molecular link between coagulation and fibrinolysis and plays a potential role in venous and arterial thrombotic diseases, much interest has been tied to the development of molecules that antagonize its function. This review aims at providing a general overview on the biochemical properties of TAFI, its (patho)physiologic function, and various strategies to stimulate the fibrinolytic system by interfering with (activated) TAFI functionality.

Keywords: TAFI; carboxypeptidase; coagulation; fibrinolysis; proCPB; proCPR; proCPU; thrombin activatable fibrinolysis inhibitor.

Publication types

  • Review

MeSH terms

  • Animals
  • Carboxypeptidase B2 / antagonists & inhibitors
  • Carboxypeptidase B2 / metabolism*
  • Enzyme Activation
  • Humans

Substances

  • Carboxypeptidase B2